Skip to main content

Month: May 2022

DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 30 APRIL 2022

  French public limited company (société anonyme) with a share capital of €1,482,202,542.50 Registered office : 1973, boulevard de la Défense 92000 Nanterre – France 552 037 806 RCS Nanterre www.vinci.com   DISCLOSURE OF THE NUMBER OF SHARES FORMING THE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS AS OF 30 APRIL 2022    Total number of shares 592,881,017Theoretical number of voting rights (including treasury stock) 592,881,017Number of voting rights (excluding treasury stock) 562,457,250  This disclosure is on VINCI web site www.vinci.com (section investors/financial information/regulatory information/7. monthly information concerning the total number of voting rights and shares that make up the company’s capital).Attachment2022 04 30 ddv English version

Continue reading

Kathryn Dolan appointed Executive Vice-President Human Resources & QHSE

PRESS RELEASE Neuilly-sur-Seine, France – May 9, 2022 Kathryn Dolan appointed Executive Vice–President Human Resources & QHSE* Bureau Veritas, a world leader in testing, inspection and certification, is pleased to announce the appointment of Kathryn Dolan, effective June 1, 2022, as Executive Vice-President Human Resources & QHSE. Kathryn Dolan will report to Didier Michaud-Daniel, Chief Executive Officer of Bureau Veritas and join the Group Executive Committee. She will replace Helen Bradley, who has decided to leave the company to pursue personal projects.   Didier Michaud-Daniel, Chief Executive Officer, Bureau Veritas, commented: “I am delighted to welcome Kathryn Dolan to the Group Executive Committee. Kathryn has the perfect blend of strategic thinking, strong operational roots and commercial focus. She will leverage...

Continue reading

Disclosure of transactions in own shares from May 02nd to May 06th, 2022

               Paris, May 09th, 2022                                            Disclosure of transactions in own shares From May 02nd to May 06th, 2022 Within the framework of the authorization granted by the General Meeting of VINCI SA of April 12, 2022 to trade in its shares and in accordance with the regulations relating to share buybacks, VINCI SA (LEI:213800WFQ334R8UXUG83) declares the purchases of treasury shares below (FR0000125486), carried out from May 02nd to May 06th, 2022 : I – Aggregate presentation by day and by marketIssuer’s name Date of transaction Identifying code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares in Euro Market (MIC code)VINCI 02/05/2022 FR0000125486 10 088 91,1767 AQEUVINCI 02/05/2022 FR0000125486 5 228 91,3359 CEUXVINCI 02/05/2022 FR0000125486 4...

Continue reading

VINCI to carry out a motorway construction project in Sydney

Nanterre, 9 May 2022 VINCI to carry out a motorway construction project in SydneyConstruction of a 7.5km section of the new M12 motorway Key environmental construction initiatives A AUD 373 million (€255 million) contractSeymour Whyte, a VINCI Construction subsidiary in Australia, has been selected by the NSW Government to build the central section of the new M12 motorway linking the future Western Sydney International (Nancy-Bird Walton) Airport to the motorway network in the Sydney area. More than 52,000 vehicles a day are expected on this new road infrastructure. The contract, worth approximately AUD 373 million (€255 million), includes the construction of 7.5km of 2×2 lanes, 11 bridges, cycle and pedestrian paths, networks, Intelligent Transport Systems (ITS) and green spaces. Seymour Whyte is targeting an “Excellent”...

Continue reading

Star Bulk Announces Date for the Release of First Quarter Ended March 31, 2022 Results, Conference Call and Webcast

ATHENS, Greece, May 09, 2022 (GLOBE NEWSWIRE) — Star Bulk Carriers Corp. (the “Company” or “Star Bulk”) (Nasdaq: SBLK), today announced that it will release its results for the first quarter ended March 31, 2022 after the market closes in New York on Tuesday, May 24, 2022. Star Bulk’s management team will host a conference call to discuss the Company’s financial results on Wednesday, May 25, 2022 at 11:00 a.m. Eastern Time (ET). Conference Call details:Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 1 (877) 553‐9962 (US Toll Free Dial In), 0(808) 238‐0669 (UK Toll Free Dial In) or +44 (0) 2071 928592 (Standard International Dial In). Please quote “Star Bulk.” Slides and audio webcast:There will also be a live, and then archived,...

Continue reading

Richardson Electronics, Ltd. to Showcase Green Energy Products at CLEANPOWER 2022

ULTRA3000® Patented Pitch Energy Module and New Products on Display LAFOX, Ill., May 09, 2022 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL) will be exhibiting in person at the CLEANPOWER event on May 16-18, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, TX. The Company’s patented ultracapacitor-based pitch energy module, the ULTRA3000®, and other new products will be on display in booth #2122. The ULTRA3000® is a proven technology for energy storage and power management within the wind turbine generator pitch system with millions of hours of operation in the field. These plug-and-play modules replace hazardous lead-acid batteries, are easy to install, reduce labor costs, and decrease downtime. “For 75 years, Richardson Electronics has been a leader in providing engineered solutions for various...

Continue reading

AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publication in JAMA Neurology1 of data showing that AC Immune’s ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. This is the first anti-Abeta vaccine study conducted with people living with DS. The landmark study was led by principal investigator Michael Rafii, MD, Ph.D.,...

Continue reading

FirstBank Maintains Robust Growth at the Start of 2022

Bank Continues to Support Down Payment Assistance Program and Contributes $250,000 to the Boulder County Wildfire Fund LAKEWOOD, Colo., May 09, 2022 (GLOBE NEWSWIRE) — FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced its 2022 first quarter summary on the company’s holdings and activities. The bank recorded year-over-year increases in assets, deposits and income, including a net income increase of 29.8 percent to $79.1 million. At the end of March, the bank’s total assets also climbed to $28.9 billion, up 11.4 percent from the same period in 2021. Total deposits were $27.1 billion, exceeding last year’s first quarter deposits by 15.5 percent, and net loan balances rose by 5.3 percent to $14.1 billion. “We’re extremely pleased with our company’s strong financial performance,”...

Continue reading

InterCure to Participate in Upcoming Investor Conferences in May 2022

NEW YORK, TORONTO, and HERZLIYA, Israel, May 09, 2022 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) today announced that that Alex Rabinovitch, Chief Executive Officer and Amos Cohen, Chief Financial Officer, will participate in the following investor conferences in May 2022. Canaccord Genuity 6th Annual Cannabis ConferenceDate: Wednesday, May 11, 2022 Cowen 2nd Annual European Cannabis ConferenceDate: Thursday, May 12, 2022 InterCure’s management team will be taking part in one-on-one meetings during the conferences. To schedule a one-on-one investor meeting with InterCure’s management team, please contact a conference representative or adam@intercure.co. About InterCure (dba Canndoc) InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U)...

Continue reading

Rackspace Technology Joins NVIDIA DGX-Ready Managed Services Program

Provides customers with the ability to leverage the power of NVIDIA DGX AI platform, free of in-house infrastructure management SAN ANTONIO, May 09, 2022 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a leading end-to-end, multicloud technology solutions company, today announced that it has joined NVIDIA’s DGX-Ready Managed Services program. The program certifies leading technology partners who are eligible to support enterprises that leverage NVIDIA DGX™ systems. As part of the relationship with NVIDIA, Rackspace Technology has also joined the NVIDIA Partner Network (NPN). NVIDIA DGX systems are an accelerated computing platform for scaling enterprise AI infrastructure. As AI adoption grows, businesses are increasingly challenged to manage the resources and infrastructure needed to manage AI development. The DGX-Ready...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.